Hypertension Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged between 18 and 82 years old.
• People who have been diagnosed with high blood pressure, with a systolic (top number) blood pressure reading of 135 mmHg or higher at home, at a clinic, or over a 24-hour monitor, and whose blood pressure medication has not changed in the last 60 days (or 30 days in certain circumstances — confirm with trial site).
• People who have moderate to severe long-term kidney disease, with a kidney function score (eGFR) between 20 and 70, whose kidney treatment has been stable as prescribed by their doctor.
• People with a kidney function score (eGFR) between 60 and 90, who also have higher-than-normal amounts of protein in their urine (at or above a certain threshold — confirm with trial site for exact values).
• People who are able and willing to attend all required follow-up appointments.
• People who are able to understand and sign a consent form agreeing to take part.

Who may not be able to join:

• People whose systolic (top number) blood pressure is over 180 mmHg even while on maximum tolerated blood pressure medication, or whose high blood pressure is caused by a treatable underlying condition (other than kidney artery narrowing or chronic kidney disease), or who are on medications known to raise blood pressure.
• People who have previously had a stent placed in a kidney artery, or have had any other procedure involving the kidney arteries, including nerve-blocking procedures around the kidneys.
• People with a kidney function score (eGFR) below 20, those currently on dialysis, or those who have received a kidney transplant.
• People with an active kidney infection, a history of or current kidney stones, polycystic kidney disease, or certain complex kidney cysts (confirm with trial site).
• People experiencing visible blood in their urine alongside a significant drop in their haemoglobin (red blood cell) levels.
• People with a haemoglobin (red blood cell) level of 9 grams per deciliter or below.
• People with bleeding disorders or abnormal blood clotting test results outside of normal ranges.
• People who have had a heart attack, a heart procedure (such as a stent or balloon procedure in the heart), a stroke, or a hospitalisation for a certain type of heart failure within the last 6 months.
• People with Type 1 diabetes, or Type 2 diabetes that is poorly controlled (HbA1c above 10%).
• People with active cancer, whether in the original site or spread to other areas, particularly involving the liver, kidneys, or abdomen.
• People who have received immune-suppressing medication in the last 3 months, or who require ongoing oxygen or breathing machine support (other than a sleep apnoea device at night).
• People whose dose of a certain class of blood pressure or kidney-protective medication (RAS inhibitors — confirm with trial site) has changed in the month before the procedure.
• People with a skin infection at the area where the treatment device would be placed.
• People with a known allergy to SonoVue®, a contrast agent used in ultrasound imaging (including allergy to sulfur hexafluoride or any of its ingredients).
• People with certain heart or lung conditions that make SonoVue® unsafe to use, such as a right-to-left heart shunt, severe pulmonary high blood pressure, uncontrolled high blood pressure, or acute respiratory distress syndrome.
• People who are unable to undergo MRI scanning, such as those with a pacemaker or other metal implants in the body, or those with severe claustrophobia.
• People who are unable to follow the study procedures due to language barriers, psychological conditions, dementia, or any other reason that prevents them from giving informed consent.
• People with known or suspected drug or alcohol misuse, or a history of not following medical instructions.
• People who work night shifts.
• People who are pregnant, breastfeeding, or planning to become pregnant during the study period.
• People who do not wish to be informed if an unexpected health finding is discovered during study-related scans or tests.
• People who are currently participating in, or have participated in, another clinical trial involving an investigational drug or device within the last 30 days.
• People who have previously been enrolled in this same trial.
• The principal investigator running the trial, as well as their family members, employees, or other people who depend on them.

Important: Always verify eligibility with the trial site directly before applying.